** Brokerage Leerink Partners starts coverage of contract research organization Medpace's MEDP.O shares with "market perform" rating and PT of $330
** Brokerage believes MEDP's growth has been affected by elevated cancellation rates and a slowdown in new clinical trial starts due to reduced biotech funding post-COVID
** Brokerage says the firm is well aligned with growing disease categories such as oncology, metabolic and cardiovascular, and its full-service outsourcing (FSO) helps smaller biotechs run efficient clinical trials
** FSO involves handling all aspects of a clinical trial that include initiating the study, analysis, monitoring of trial subjects, ensuring safety and interacting with regulatory bodies
** Brokerage says its PT reflects higher growth prospects and profitability compared with its peers such as IQVIA IQV.N and ICLR ICLR.O
** 4 out 10 brokerages rate the stock "buy" or higher, 6 "hold", median PT $350, according to LSEG data
** As of last close, MEDP stock down 21.5% in past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.